High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation
Christa E. Nath(Children's Hospital at Westmead), Peter J. Shaw(Children's Hospital at Westmead), Howard Gurney(Radboud University Nijmegen), Andrew J. McLachlan(The University of Sydney), Ian Kerridge(The University of Sydney), Yiu Lam Kwan(Concord Repatriation General Hospital), Campbell Tiley(Gosford Hospital), Lihua Zeng(Children's Hospital at Westmead), Judith Trotman(The University of Sydney), John Earl(Children's Hospital at Westmead), Peter Presgrave(Wollongong Hospital), Douglas Joshua(Royal Prince Alfred Hospital), Ian Nivison‐Smith
Cited by 59
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
|Journal of Clinical Epidemiology|2012|1.2k